{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-26-000013","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.453746+00:00","generated_at":"2026-05-15T01:46:39.328008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q1 adjusted EPS $2.65 (+7.7%), revenue $15.0B (+12.4%); raises FY2026 guidance","bullets":["GAAP diluted EPS $0.39, down 45.8%; adjusted EPS $2.65, up 7.7%, with $0.41 IPR&D headwind.","Net revenue $15.002B, +12.4% reported / +10.3% operational; immunology portfolio $7.290B (+16.4%).","Skyrizi $4.483B (+30.9%), Rinvoq $2.119B (+23.3%), Humira $688M (-38.6%); neuroscience +26%.","FY2026 adjusted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16.","FDA CRL for trenibotulinumtoxinE on manufacturing; no safety/efficacy issues; expects prompt refiling."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-26-000013","json":"https://secwatch.observer/filing/0001551152-26-000013.json","markdown":"https://secwatch.observer/filing/0001551152-26-000013.md","text":"https://secwatch.observer/filing/0001551152-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/0001551152-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:46:39.328008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6010523864cacef3cc1a5781df4fb48d9f23423","claim":"AbbVie Inc. reported the first quarter ended March 31, 2026 results: revenue $15.002 billion, EPS $0.39. Guidance raised.","evidence_excerpt":"Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/0001551152-26-000013-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$15.002 billion"},{"label":"EPS","value":"$0.39"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}